Article contents
Supplement 4: Canadian Guidelines on Parkinson's Disease
Published online by Cambridge University Press: 02 December 2014
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Other
- Information
- Copyright
- Copyright © The Canadian Journal of Neurological 2012
References
1Gibb, WR, Lees, AJ.The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745–52.CrossRefGoogle Scholar
2Schrag, A, Ben-Shlomo, Y, Quinn, N.How valid is the clinical diagnosis of Parkinson’s disease in the community? J Neurol Neurosurg Psychiatry. 2002;73(5):529–34.CrossRefGoogle ScholarPubMed
3Olanow, CW, Rascol, O, Hauser, R, et al.A double-blind, delayedstart trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361 (13):1268–78.CrossRefGoogle ScholarPubMed
4Schapira, AH, Obeso, J.Timing of treatment initiation in Parkinson’s disease: a need for reappraisal? Ann Neurol. 2006;59(3):559–62.CrossRefGoogle ScholarPubMed
5Stocchi, F, Rascol, O, Kieburtz, K, et al.Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18–27.CrossRefGoogle ScholarPubMed
6Weintraub, D, Koester, J, Potenza, MN, et al.Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–95.CrossRefGoogle ScholarPubMed
7Hassan, A, Bower, JH, Kumar, N, et al.Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat Disord. 2011;17(4):260–4.CrossRefGoogle ScholarPubMed
8Moro, E, Lozano, AM, Pollak, P, et al.Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson’s disease. Mov Disord. 2010;25(5):578–86.CrossRefGoogle ScholarPubMed
9Hamani, C, Lozano, AM.Hardware-related complications of deep brain stimulation: a review of the published literature. Stereotact Funct Neurosurg. 2006;84(5-6):248–51.CrossRefGoogle ScholarPubMed
10Hariz, MI, Rehncrona, S, Quinn, NP, Speelman, JD, Wensing, C.Multicenter study on deep brain stimulation in Parkinson’s disease: an independent assessment of reported adverse events at 4 years. Mov Disord. 2008;23(3):416–21.CrossRefGoogle ScholarPubMed
11Deuschl, G, Schade-Brittinger, C, Krack, P, et al.A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2006;355(9):896–908.CrossRefGoogle ScholarPubMed
12Weaver, FM, Follett, K, Stern, M, et al.Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63–73.CrossRefGoogle ScholarPubMed
13Pahwa, R, Lyons, KE, Wilkinson, SB, et al.Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg. 2006;104(4): 506–12.CrossRefGoogle ScholarPubMed
14Hariz, MI, Krack, P, Alesch, F, et al.Multicentre European study of thalamic stimulation for parkinsonian tremor: a 6 year follow-up. J Neurol Neurosurg Psychiatry. 2008;79(6):694–9.CrossRefGoogle Scholar
15Derost, PP, Ouchchane, L, Morand, D, et al.Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology. 2007;68(17):1345–55.CrossRefGoogle Scholar
16Schupbach, WM, Maltete, D, Houeto, JL, et al.Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology. 2007;68(4):267–71.CrossRefGoogle ScholarPubMed
17Ravina, B, Camicioli, R, Como, PG, et al.The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69(4):342–7.CrossRefGoogle ScholarPubMed
18Menza, M, Dobkin, RD, Marin, H, et al.A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72(10):886–92.CrossRefGoogle ScholarPubMed
19Antonini, A, Tesei, S, Zecchinelli, A, et al.Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effect on quality of life. Mov Disord. 2006;21(8):1119–22.CrossRefGoogle ScholarPubMed
20Devos, D, Dujardin, K, Poirot, I, et al.Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23(6):850–7.CrossRefGoogle ScholarPubMed
21Weintraub, D, Mavandadi, S, Mamikonyan, E, et al.Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75(5):448–55.CrossRefGoogle ScholarPubMed
22Barone, P, Poewe, W, Albrecht, S, et al.Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573–80.CrossRefGoogle ScholarPubMed
23Friedman, JH.Parkinson’s disease psychosis 2010: a review article. Parkinsonism Relat Disord. 2010;16(9):553–60.CrossRefGoogle ScholarPubMed
24Rabey, JM, Prokhorov, T, Miniovitz, A, Dobronevsky, E, Klein, C.Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007;22(3):313–8.CrossRefGoogle ScholarPubMed
25Shotbolt, P, Samuel, M, Fox, C, David, AS.A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat. 2009;5:327–32.CrossRefGoogle ScholarPubMed
26Merims, D, Balas, M, Peretz, C, Shabtai, H, Giladi, N.Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol. 2006;29(6): 331–7.CrossRefGoogle ScholarPubMed
27Hely, MA, Reid, WG, Adena, MA, Halliday, GM, Morris, JG.The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–44.CrossRefGoogle Scholar
28Aarsland, D, Ballard, C, Walker, Z, et al.Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–8.CrossRefGoogle ScholarPubMed
29Grace, J, Amick, MM, Friedman, JH.A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry. 2009;80(1):18–23.CrossRefGoogle ScholarPubMed
30Emre, M, Tsolaki, M, Bonuccelli, U, et al.Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77.CrossRefGoogle ScholarPubMed
31Dauvilliers, Y.Insomnia in patients with neurodegenerative conditions. Sleep Med. 2007;8 Suppl 4:S27–34.CrossRefGoogle ScholarPubMed
32Montgomery, P, Dennis, J.A systematic review of nonpharmacological therapies for sleep problems in later life. Sleep Med Rev. 2004;8(1):47–62.CrossRefGoogle ScholarPubMed
33Dowling, GA, Mastick, J, Colling, E, Carter, JH, Singer, CM, Aminoff, MJ.Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med. 2005;6(5):459–66.CrossRefGoogle ScholarPubMed
34Medeiros, CA, Carvalhedo de Bruin, PF, Lopes, LA, Magalhaes, MC, de Lourdes Seabra, M, de Bruin, VM.Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease. A randomized, double blind, placebo-controlled study. J Neurol. 2007;254(4):459–64.CrossRefGoogle ScholarPubMed
35Leeman, AL, O’Neill, CJ, Nicholson, PW, et al.Parkinson’s disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol. 1987;24(5):637–43.CrossRefGoogle ScholarPubMed
36Stocchi, F, Barbato, L, Nordera, G, Berardelli, A, Ruggieri, S.Sleep disorders in Parkinson’s disease. J Neurol. 1998;245 Suppl 1:S15–8.CrossRefGoogle ScholarPubMed
37Menza, M, Dobkin, RD, Marin, H, et al.Treatment of insomnia in Parkinson’s disease: a controlled trial of eszopiclone and placebo. Mov Disord. 2010;25(11):1708–14.CrossRefGoogle ScholarPubMed
38Zesiewicz, TA, Sullivan, KL, Arnulf, I, et al.Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74(11):924–31.CrossRefGoogle Scholar
39Gagnon, JF, Postuma, RB, Mazza, S, Doyon, J, Montplaisir, J.Rapideye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol. 2006;5(5):424–32.CrossRefGoogle ScholarPubMed
40Gagnon, JF, Postuma, RB, Montplaisir, J.Update on the pharmacology of REM sleep behavior disorder. Neurology. 2006;67(5):742–7.CrossRefGoogle ScholarPubMed
41Aurora, RN, Zak, RS, Maganti, RK, et al.Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85–95.Google ScholarPubMed
42Ferini-Strambi, L, Manconi, M.Treatment of restless legs syndrome. Parkinsonism Relat Disord. 2009;15 Suppl 4:S65–70.CrossRefGoogle ScholarPubMed
43Arnulf, I.Excessive daytime sleepiness in parkinsonism. Sleep Med Rev. 2005;9(3):185–200.CrossRefGoogle ScholarPubMed
44Cochen De Cock, V, Abouda, M, Leu, S, et al.Is obstructive sleep apnea a problem in Parkinson’s disease? Sleep Med. 2010;11(3):247–52.CrossRefGoogle ScholarPubMed
45Adler, CH, Caviness, JN, Hentz, JG, Lind, M, Tiede, J.Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord. 2003;18(3):287–93.CrossRefGoogle ScholarPubMed
46Ondo, WG, Fayle, R, Atassi, F, Jankovic, J.Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76(12):1636–9.CrossRefGoogle ScholarPubMed
47Hogl, B, Saletu, M, Brandauer, E, et al.Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25(8):905–9.CrossRefGoogle ScholarPubMed
48Magerkurth, C, Schnitzer, R, Braune, S.Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily life. Clin Auton Res. 2005;15(2):76–82.CrossRefGoogle ScholarPubMed
49Chaudhuri, KR, Healy, DG, Schapira, AH.Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–45.CrossRefGoogle ScholarPubMed
50Bachmann, CG, Trenkwalder, C.Body weight in patients with Parkinson’s disease. Mov Disord. 2006;21(11):1824–30.CrossRefGoogle ScholarPubMed
51Barichella, M, Cereda, E, Pezzoli, G.Major nutritional issues in the management of Parkinson’s disease. Mov Disord. 2009;24(13):1881–92.CrossRefGoogle ScholarPubMed
52Naumann, M, So, Y, Argoff, CE, et al.Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1707–14.CrossRefGoogle Scholar
53Hyson, HC, Johnson, AM, Jog, MS.Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord. 2002;17 (6):1318–20.CrossRefGoogle ScholarPubMed
54Molloy, L.Treatment of sialorrhoea in patients with Parkinson’s disease: best current evidence. Curr Opin Neurol. 2007;20(4):493–8.CrossRefGoogle ScholarPubMed
55Thomsen, TR, Galpern, WR, Asante, A, Arenovich, T, Fox, SH.Ipratropium bromide spray as treatment for sialorrhea in Parkinson’s disease. Mov Disord. 2007;22(15):2268–73.CrossRefGoogle ScholarPubMed
56Simuni, T, Sethi, K.Nonmotor manifestations of Parkinson’s disease. Ann Neurol. 2008;64 Suppl 2:S65–80.CrossRefGoogle ScholarPubMed
57Chancellor, MB, Anderson, RU, Boone, TB.Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil. 2006;85(6):536–45.CrossRefGoogle ScholarPubMed
58Mostile, G, Jankovic, J.Treatment of dysautonomia associated with Parkinson’s disease. Parkinsonism Relat Disord. 2009;15 Suppl 3:S224–32.CrossRefGoogle ScholarPubMed
59Santos, JC, Telo, ER.Solifenacin: scientific evidence in the treatment of overactive bladder. Arch Esp Urol. 2010;63(3):197–213.Google ScholarPubMed
60Abbott, RD, Ross, GW, Petrovitch, H, et al.Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord. 2007;22(11):1581–6.CrossRefGoogle ScholarPubMed
61Goldstein, DS.Orthostatic hypotension as an early finding in Parkinson’s disease. Clin Auton Res. 2006;16(1):46–54.CrossRefGoogle ScholarPubMed
62Schoffer, KL, Henderson, RD, O’Maley, K, O’sullivan, JD.Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s disease. Mov Disord. 2007;22(11):1543–9.CrossRefGoogle ScholarPubMed
You have
Access
- 78
- Cited by